Penn Capital Management Company LLC Purchases Shares of 495,945 Health Catalyst, Inc. (NASDAQ:HCAT)

Penn Capital Management Company LLC acquired a new stake in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 495,945 shares of the company's stock, valued at approximately $3,506,000. Penn Capital Management Company LLC owned about 0.82% of Health Catalyst as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in shares of Health Catalyst during the fourth quarter valued at approximately $29,000. Stoneridge Investment Partners LLC bought a new stake in shares of Health Catalyst during the fourth quarter valued at about $77,000. Martin Worley Group acquired a new stake in Health Catalyst in the fourth quarter worth about $78,000. OneAscent Financial Services LLC bought a new position in Health Catalyst during the 4th quarter valued at $97,000. Finally, ExodusPoint Capital Management LP acquired a new position in shares of Health Catalyst during the 4th quarter valued at $107,000. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Stock Performance

Shares of HCAT stock traded up $0.12 during mid-day trading on Friday, reaching $4.10. The stock had a trading volume of 600,761 shares, compared to its average volume of 613,038. The firm has a market cap of $287.87 million, a PE ratio of -3.04 and a beta of 1.43. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst, Inc. has a one year low of $3.56 and a one year high of $9.24. The firm's 50 day simple moving average is $4.30 and its 200 day simple moving average is $6.22.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on HCAT shares. Piper Sandler lowered their target price on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating on the stock in a report on Tuesday, February 11th. Royal Bank of Canada cut their price objective on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a report on Thursday, February 27th. Stifel Nicolaus reduced their price target on shares of Health Catalyst from $10.00 to $5.00 and set a "hold" rating for the company in a research report on Thursday, February 27th. KeyCorp lowered their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 16th. Finally, Evercore ISI cut Health Catalyst from an "outperform" rating to an "inline" rating in a research report on Wednesday, April 9th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Health Catalyst currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.05.

Insider Buying and Selling

In related news, General Counsel Benjamin Landry sold 13,827 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the sale, the general counsel now owns 160,437 shares of the company's stock, valued at $729,988.35. The trade was a 7.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Daniel Lesueur sold 16,902 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total value of $76,397.04. Following the completion of the transaction, the chief operating officer now directly owns 216,250 shares of the company's stock, valued at approximately $977,450. The trade was a 7.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,588 shares of company stock valued at $225,906 over the last ninety days. 2.50% of the stock is owned by company insiders.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.